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Available online 16 November 2016Objective: Both Tourette's disorder (TD) and attention-deﬁcit/hyperactivity disorder (ADHD) have been related
to abnormalities in glutamatergic neurochemistry in the fronto-striatal circuitry. TD and ADHD often co-occur
and the neural underpinnings of this co-occurrence have been insufﬁciently investigated in prior studies.
Method:We used protonmagnetic resonance spectroscopy (1H-MRS) in children between 8 and 12 years of age
(TD n=15, ADHD n=39, TD+ADHD n=29, and healthy controls n=53) as an in vivomethod of evaluating
glutamate concentrations in the fronto-striatal circuit. Spectra were collected on a 3 Tesla Siemens scanner from
two voxels in each participant: the anterior cingulate cortex (ACC) and the left dorsal striatum. LC-model was
used to process spectra and generate glutamate concentrations in institutional units. A one-way analysis of var-
iance was performed to determine signiﬁcant effects of diagnostic group on glutamate concentrations.
Results:Wedid not ﬁnd any group differences in glutamate concentrations in either the ACC (F(3132)= 0.97, p=
0.41) or striatum (F(3121) = 0.59, p= 0.62). Furthermore, variation in glutamate concentration in these regions
was unrelated to age, sex, medication use, IQ, tic, or ADHD severity. Obsessive–compulsive (OC) symptomswere
positively correlatedwith ACCglutamate concentrationwithin the participantswith TD (rho=0.35, puncorrected=
0.02).
Conclusion:We foundno evidence for glutamatergic neuropathology in TDorADHDwithin the fronto-striatal cir-
cuits. However, the correlation of OC-symptoms with ACC glutamate concentrations suggests that altered gluta-
matergic transmission is involved in OC-symptoms within TD, but this needs further investigation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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MRS1. Introduction
Tourette's disorder (TD) and attention-deﬁcit/hyperactivity disorder
(ADHD) are early onset neurodevelopmental disorders affecting ap-
proximately 1% (Robertson, 2008) and 5% (Polanczyk et al., 2007) of
children and adolescents, respectively. While TD is characterized by
the presence of motor and vocal tics (American Psychiatric
Association, 2013) there are also psychiatric comorbidities present indywas presented as a poster at
esearch on Impulsivity, 2015,
he Study of Tourette Syndrome
uroscience, Donders Institute of
l Centre, P.O. Box 9101, 6500HB
. This is an open access article underup to 86% of those with TD during their lifetime (Hirschtritt et al.,
2015). ADHD is the most common, occurring in approximately 40% of
cases (Rickards, 2011) and even more TD patients have ADHD symp-
toms that do not meet the threshold for diagnosis (Robertson, 2000).
Conversely, the presence of ticswithin patients with ADHDhas been es-
timated at 20% (Roessner et al., 2007). ADHD itself is characterized by
age inappropriate inattention and/or hyperactivity/impulsivity leading
to impaired functioning (American Psychiatric Association, 2013).
Both disorders have been associated with abnormalities in fronto-
striatal circuits (Leisman and Melillo, 2013; Mink, 2006), although the
overlap in conditions has confounded research to date. Structural and
functional neuroimaging studies have reported alterations in the cau-
date nuclei, putamen, and anterior cingulate cortex (ACC) in TD
(Peterson et al., 2003; Ganos et al., 2013) and ADHD (Frodl and
Skokauskas, 2012; Nakao et al., 2011; Hart et al., 2013) relative to con-
trols, although not always consistently. It has been proposed that excit-
atory abnormalities in the striatum cause erroneous inhibition of
neurons in the globus pallidus (GP) internus, which in turn leads tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Albin and Mink, 2006). These striatal abnormalities may also underlie
the high rate of comorbidity with other disorders, like ADHD and obses-
sive compulsive disorder (OCD) (Hirschtritt et al., 2015) due to the aber-
rant integrative interplay of different fronto-striatal circuits including
connections with the ACC (Albin and Mink, 2006; Mink, 2001). Dopa-
mine dysfunction within the fronto-striatal circuit has long been consid-
ered the primary cause of tics (Singer et al., 1982) and has been related to
difﬁculties with attention and impulsivity (Swanson et al., 2007). How-
ever, as glutamatergic, GABAergic, serotonergic, cholinergic, and opioid
aswell as dopaminergic systems all operatewithin the fronto-striatal cir-
cuits it is plausible that multiple neurotransmitter systems may be in-
volved in TD and ADHD (Singer et al., 2010). Glutamate is the primary
excitatory neurotransmitter found in the brain (Monaghan et al., 1985;
Pittenger et al., 2011), essential in fronto-striatal transmission and
often co-transmitted with dopamine (Chuhma et al., 2009). Post-
mortem analysis of a small number of brains from people who had TD
corroborates the view that glutamate is involved in TD as reduced levels
of glutamate were seen in the GP and substantia nigra of the TD brains
compared to control brains (Anderson et al., 1992).
Additional insights into the underlying neurobiology of TD andADHD
canbe found by investigating brain neurochemistry. This can be achieved
by using proton magnetic resonance spectroscopy (1H-MRS) which al-
lows for non-invasive in vivo quantiﬁcation of speciﬁc neurometabolites.
There have been just four MRS studies of TD to date, three of which fo-
cused on GABA concentrations either in the primary and secondary
motor areas (Draper et al., 2014) or the sensory motor cortex (Tinaz et
al., 2014; Puts et al., 2015). DeVito et al. (2005) on the other hand inves-
tigatedmultiple neurochemicals including Glx, the combined signal from
glutamatergic compounds (glutamate+ glutamine), withinmultiple re-
gions; premotor cortex, caudate nucleus, putamen and thalamus with a
3 Tesla scanner in a sample of 25 (male only) children and adolescents
with TD in comparison to controls. No group differences were seen in
Glx in any of the regions.Within the putamen lower creatine (Cre) levels
bilaterally and lower N-acetyl aspartate and choline in the left putamen
were found. Reduced Cre bilaterally in the caudate nucleus was also
seen but this did not reach signiﬁcance.
Many more MRS studies of disorders related to TD, such as ADHD
and OCD, have been conducted. For a review of these studies in ADHD,
OCD and autism spectrum disorder (ASD) see Naaijen et al. (2015).
However, ﬁndings were inconsistent, plagued by heterogeneous meth-
odologies, sample selection (i.e., child or adult, inclusion or exclusion of
comorbidities), voxel placement, and often inadequate ﬁeld strengths
to distinguish glutamate from glutamine (Naaijen et al., 2015). Despite
these issues the review tentatively summarized that increased striatal
Glx levels are associated with both ADHD and OCD and increased ACC
Glx levels with pediatric ADHD.
In the current study we assessed a large number of children between
the ages of 8 and 12 years which allowed us to focus on a group where
tics are most frequently observed and not limit ourselves to the subset
of patients whose tics persist into adulthood (Bloch and Leckman,
2009). Furthermore we directly addressed the confounds of comorbidity
rampant in previous studies by including a TD+ADHDgroup in addition
to ADHD, TD, and healthy control (HC) groups. Based on previous ﬁnd-
ings in childhood ADHD (Naaijen et al., 2015), we expected increased
glutamate concentrations in both regions of interest. This is the ﬁrst
study to investigate fronto-striatal glutamate in children with TD. Given
the theory that excitatory abnormalities in the striatum result in tics,
we expected to observe raised glutamate in the striatum of TD patients.
2. Method
2.1. Participants
Participants with TD and/or ADHD: TD with/without ADHD n= 60,
ADHD without TD n = 60 were recruited via child and adolescentpsychiatry departments and patient associations throughout the Neth-
erlands, while healthy controls (HC; n = 60) were found mainly
through schools. The ﬁnal numbers included for analysis (i.e. with us-
able data) can be found in Section 3.1 and Table 1 (n = 136 for the
ACC and n=125 for the striatum). Written informed consent was pro-
vided by the parents/guardians of all participants and written assent
was also given by participants who were 12 years of age. This study
was approved by the regional ethics board (CMO Regio Arnhem-Nijme-
gen, numbers: NL42004.091.12 & NL48377.091.14).
Inclusion criteria for all participants included being aged 8–12 years,
IQ N 70, Caucasian decent, no previous head injuries or neurological dis-
orders, no contraindications for MRI assessment, and nomajor physical
illness. Inclusion criteria for ADHD and TDwere meeting DSM-5 criteria
for these disorders. Those with sub-threshold ADHD (Kiddie Schedule
for Affective Disorders and Schizophrenia (K-SADS Kaufman et al.,
1997) score of 4 or 5 on either subscale) were also included. Persistent
Motor or Vocal Tic Disorder (Motor type) was also allowed for the TD
group. Common psychiatric comorbidities like oppositional deﬁant dis-
order were not excluded. Within the TD group, ADHD, and OCD were
not excluded, while in the ADHD group those with tics and/or OCD
were excluded. Within the HC group no psychiatric disorders were
allowed, as determined by screening questionnaires (Child Behavior
Checklist [CBCL] and Teacher Report Form [TRF] Bordin et al., 2013).
Subjects were divided into four groups; HC, TD, ADHD, and
TD + ADHD, see Table 1 for demographics. Participants were required
to refrain from consuming caffeine on the day of testing. Medications
for ticswere continued asnormalwhile stimulantmedicationwaswith-
held for 48 h before testing.
2.2. Phenotypic information
TD diagnosis was conﬁrmed, and tic severity rated, by diagnostic in-
terview with parent(s) and child present using the Yale Global Tic Se-
verity Scale (YGTSS Leckman et al., 1989). To determine the presence
of ADHD and/or other psychiatric disorders the K-SADS (Kaufman et
al., 1997) interview was administered to the parent(s). All interviews
were conducted by experienced researchers who were trained and
overseen by a child- and adolescent psychiatrist (JKB). The screening
module was used, followed if needed by disorder-speciﬁc modules. If
participants screened positive for possible OCD the Children's Yale-
Brown Obsessive Compulsive Scale (CY-BOCS Scahill et al., 1997) was
administeredwith both parent(s) and child present. The CY-BOCS inter-
viewwas conductedwith eachparticipant of the TDgroupdue to the re-
latedness of symptoms and common co-occurance of OCD and TD.
Full-scale IQ was estimated by four subtests of the Wechsler Intelli-
gence Scale for Children-III (WISC-IIIWechsler, 2002): Vocabulary, Sim-
ilarities, Block design, and Picture completion. Questionnaires were
further used to assess phenotypic traits. The Conners' Parent Rating
Scale — Revised Long version (CPRS-RL Conners et al., 1997) was used
to rate ADHD severity. Additional questionnaires were used to assess
the presence of autistic symptoms and compulsive behaviors; the
Children's Social Behavioral Questionnaire (CSBQ Luteijn et al., 2000)
and Repetitive Behavior Scale (RBS-R Lam and Aman, 2007). Informa-
tion about medication history was gathered from parental report
which has previously been shown to correlate well with pharmacy re-
cords (Kuriyan et al., 2014). Interviews on psychiatric symptoms were
conducted about an unmedicated period.
2.3. T1-weighted MRI acquisition
AllMRI datasetswere acquired on the same3 T Siemens Prisma (Sie-
mens, Erlangen, Germany) scanner located in the Donders Institute for
Brain, Cognition and Behaviour, Nijmegen, the Netherlands. T1-weight-
ed anatomical images were acquired with a transversal, 3D magnetiza-
tion prepared rapid gradient echo (MPRAGE) parallel imaging sequence
with the following parameters: TR = 2300 ms, TE = 2.98 ms, TI =
Table 1
Demographic description of participants included in the ACC analysis.
Control TD ADHD TD + ADHD Test statistic p-Value
N 53 15 39 29
Age years, mean(SD) 10.0(1.0) 10.4(1.2) 10.7(1.2) 10.7(1.6) K-W χ2 = 2.98 0.40
Sex, m/f 38/15 13/2 21/18 25/4 χ2 = 10.70 0.01⁎
aIQ, mean(SD)
Range
109(11), 86–133 105(12), 81–126 103(13), 71–137 106(11), 85–124 F = 2.47 0.06
Handed, r/l 48/5 14/1 36/3 25/4 χ2 = 0.90 0.82
bADHD severity, mean(SD) T = 45.5(4.9) T = 51.7(7.0) T = 71.9(9.7) T = 68.7(9.1) t = 1.37 0.18†
I = 45.5(6.0) I = 50.9(8.2) I = 69.3(10.0) I = 65.2(9.8) t = 1.69 0.10†
H = 46.1(3.7) H = 52.2(8.5) H = 71.2(11.1) H = 70.0(10.4) t = −0.44 0.66†
CSBQ core autism score, mean(SD) 1.42(1.89) 9.53(10.58) 12.46(7.78) 17.66(9.40)
RBS compulsivity score, mean(SD) 0.09(0.35) 1.67(1.59) 0.69(1.24) 2.55(3.00)
cTic dx, n – TD = 14 – TD = 29
CMT = 1
cTic severity, mean(SD) – T = 20.4(7.9) – T = 20.8(9.2) t = −0.13 0.89
M = 13.6(4.3) M = 13.1(5.5) t = 0.33 0.75
V = 6.8(4.7) V = 7.7(5.7) K-W χ2 = 0.22 0.64
cAge tic onset years, mean(SD) – 5.3(1.7) – 5.7(1.7) t = −0.75 0.46
cDuration since tic onset years, mean(SD) – 5.0(1.8) – 5.0(2.0) t = 0.06 0.95
dOCD dx, n – 3 – 6
dOC-symptoms, mean(SD) – 8.47(8.6) – 6.75(8.4) K-W χ2 = 0.78 0.38
eMedication –
Stimulant 0 24 9
Strattera 0 1 0
Antipsychotic 2 1 7
Clonidine 0 0 2
ADHD, attention-deﬁcit/hyperactivity disorder; CSBQ, Children's Social Behavioral Questionnaire; CMT, chronic motor tic; dx, diagnosis; H, hyperactive; I, inattentive; C, combined; K-W,
Kruskal–Wallis;M,motor;m/f, male/female; OCD, obsessive compulsive disorder; r/l, right/left; RBS, Repetitive Behavior Scale; SD, standard deviation; t,Welch two sample t-test; T, total;
TD, Tourette's disorder; V, vocal.
a IQ estimated from a subtest of the Wechsler Intelligence Scale for Children-III (WISC-III Wechsler, 2002) rating.
b ADHD severity ratings reﬂect T-scores from the Conners' Parent Rating Scale — Revised Long version (Conners et al., 1997).
c Tic diagnosis and severity were determined and rated with the Yale Global Tic Severity Scale (Leckman et al., 1989). Tic severity is reported excluding impairment score.
d OCD diagnosis was determined as a total-score of ≥16 on the Children's Yale-Brown Obsessive Compulsive Scale (Scahill et al., 1997).
e Current medication status, determined from parental report of current and previous medication use.
† Statistics refer to an ADHD versus TD + ADHD contrast.
⁎ p b 0.05.
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plane resolution = 1.0 × 1.0 mm, acceleration factor = 2, acquisition
time = 5:30 min. Each participant also had their head stabilized with
cushions during scanning and had a piece of tape across their foreheads
to help awareness of possible movement while scanning. All partici-
pants were ﬁrst familiarized with the MRI procedure in a mock scanner
where the importance of lying still was explained.2.4. MRS acquisition
Proton spectra were acquired using a point resolved spectroscopy
(PRESS) sequence in two regions of interest, with chemically selective
suppression (CHESS) water suppression (Haase et al., 1985). A single
8 cm3 voxel was centered on the midline covering the pregenual ACC
anterior and slightly superior to the genu of the corpus callosum
(TR = 3000 ms, TE = 30 ms, number of averages = 96, bandwidth =
5 kHz, number of points = 4096). A second, similar voxel was located
in the left dorsal striatum covering the caudate nucleus and putamen.
Unsuppressedwater reference spectra (16 averages)were also acquired
as part of the standard acquisition. See Fig. 1 for location of the voxels
and an example spectrum. Both voxels were placed to include a maxi-
mum amount of grey matter and a minimum amount of cerebrospinal
ﬂuid (CSF). T1-weighted images were used for voxel placement and
later for tissue segmentation during processing. Acquisition time was
6 min per voxel.2.5. Processing
LCModel, version V6.03-0I (Provencher, 1993, 2001), was used to
conduct spectral analysis. LCModel uses a linear combination ofsimulated or in vitro metabolite solution spectra as a reference to iden-
tify and quantify the major resonance of in vivo spectra.
Water referencedmetabolite concentrationswere automatically cal-
culated in institutional units (i.u.). Institutional units are presented
since we did not correct for the T1 and T2 relaxation times of themetab-
olites or the T1 relaxation time of water. The T2 of tissue water was
corrected for assuming the signal had decayed by 30% at the echo
time (Lu et al., 2005). No correctionwasmade for the T2 decay ofmetab-
olites. In addition, there are other scanner-dependent factors that can
affect the absolute scaling (e.g., details of coil combination), such that
metabolite concentrations measured in i.u. are preferred over
attempting to scale to absolute concentrations in millimolar (mM).
The uniﬁed segmentation procedure within the VBM8 toolbox of
SPM8 (Statistical Parametric Mapping release 8, London, UK) was used
to process the T1 images and produce grey matter (GM), white matter
(WM), and CSF probability maps. Spectroscopy voxels were mapped
onto these maps to provide the partial volume of GM, WM, and CSF
within each spectroscopy voxel (fGM, fWM, and fCSF), and to allow for
group comparisons of the placement of the spectroscopy voxels. Addi-
tionally, to correct for differing amounts of water in each tissue and
for partial volume effectswe corrected individualmetabolite concentra-
tions for water concentrations with the following formula (Gasparovic
et al., 2006):
Metabolitecorrected
¼ MetaboliteRaw  43;300  fGM þ 35;880  fWM þ 55;556  fCSFð Þ=35;880ð Þ
 1= 1− fCSFð Þð Þ
where 43,300, 35,880, and 55,556 are the water concentrations in mM
for GM, WM, and CSF (Ernst et al., 1993), respectively, as described by
the LCModel manual (Provencher, 2014). These concentrations
Fig. 1. Location of the two voxels are shown on a T1-weighted anatomical image for the pregenual ACC including an example spectrum (top) and the left dorsal striatum including an
example spectrum (bottom). Peaks corresponding to individual metabolites are highlighted. The thin black line represents the frequency-domain data, the red line is the LCModel ﬁt.
In the top panel the residuals are plotted (the data minus the ﬁt). Cho, choline; Cre, creatine; Gln, glutamine; Glu, glutamate; Glx, Glu + Gln; mI, myo-inositol; NAA, N-acetylaspartate.
19J. Naaijen et al. / NeuroImage: Clinical 13 (2017) 16–23correspond to 77.9, 64.4 and 100%, respectively, assuming that CSF is
purewater (Ernst et al., 1993). This includes a correction for the fraction
of the MRS voxel occupied by CSF, along with corrections for the water
concentration in each of the tissue types. The factor 35,880 in the de-
nominator is included since the initial LCModel analysis was carried
out assuming the voxel was pure WM.
2.6. Quality control
Statistical analyses were restricted to spectra with linewidth (full-
width at half-maximum; FWHM) ≤ 0.1 ppm, Cramér-Rao lower bounds(CRLB) ≤ 20%, signal to noise ratio ≥ 5 or corrected glutamate concen-
trations less than two standard deviations from the mean. Further-
more, anatomical scan quality was visually checked as these were
used for voxel placement and tissue segmentation. Fifteen partici-
pants were excluded from both analyses due to poor structural
scan quality. A further seven spectra from the ACC (n = 136) and
20 spectra from the striatal analyses (n = 125) were excluded
based on spectral quality. In addition to the exclusion of those with
≥20% CRLB values, we investigated group differences in CRLBs to ver-
ify that possible differences in glutamate levels were not due to dif-
ferences in CRLBs (Kreis, 2015).
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Statistical analyses were conductedwith the R statistical program (R
Core Team, 2013). Differences between the four groups in categorical
measures were tested with Pearson's chi-squared tests. Group differ-
ences in continuous measures were assessed with a one way analysis
of variance (ANOVA) orWelch Two Sample t-test if assumptions of ho-
mogeneity of variance and normality of distributionsweremet (p N 0.05
in Bartlett test of homogeneity of variance and Shapiro–Wilk normality
test). If these assumptions were violated a non-parametric Kruskal–
Wallis rank sum test was used. ADHD severity was only tested between
the ADHD and TD+ADHDgroup. Similarlymeasures related to tics and
OC-symptoms were only tested between the TD and TD + ADHD
groups.
Group differences in voxel tissue composition and spectral quality
were assessed with a ANOVA. Group differences in glutamate were an-
alyzed ﬁrst with age and sex included as covariates. These covariates
were removed from analysis as they did not signiﬁcantly contribute to
themodel. This resulted in the use of an ANOVA followed if appropriate
by Bonferroni corrected post-hoc pairwise t-tests. The inﬂuence of IQ,
ADHD severity, ASD symptoms, repetitive and compulsive behaviors,
and medication status were also examined by inclusion in an ANCOVA.
Correlations between glutamate levels and phenotypic measures of
those with TD (tic severity, age of onset and duration since tic onset,
and OC-symptoms) were assessed with Pearson's correlation tests if
normally distributed or Spearman's rank correlation rho test if not.
Tests were then Bonferroni corrected for multiple comparisons. In the
supplementary material we added the same analysis for Glx.
3. Results
3.1. Demographics
MR spectra were acquired for a total of 162 of the original 180 par-
ticipants. Three participants from the ADHD group were found not to
have ADHD (K-SADS b 4 in both subscales) and one presented with
tics but did not meet criteria for TD or Chronic Motor Tic disorder
(CMT). These four participants were thereafter excluded from analysis.
Due to spectral or segmentation quality concerns 22 spectra were ex-
cluded from the ACC analysis (n=136) and 35 from the striatal analysis
(n=125). The TD groupwas subdivided into those that also had ADHD
(TD+ADHD; n=29, 27 for the ACC and striatal analyses, respectively)
and those that did not (TD; n=15, 17 for the ACC and striatal analyses,
respectively). Participants with sub-threshold ADHD were included in
either the ADHD group or the TD + ADHD group if comorbid with TD.
Details of the groups used for analysis of the ACC are reported in Table
1 (n= 136).
Analysis of the striatum included fewer participants (n= 125) due
to exclusion based on spectral quality (n=22). This did not signiﬁcant-
ly alter the demographic distributions between groups (n= 48, 17, 33,
and 27 for the HC, TD, ADHD, and TD+ ADHD groups, respectively) re-
garding age (K-W χ2 = 1.64, p = 0.65), sex (χ2=8.09, p = 0.04), IQ
(F(3117) = 2.25, p = 0.09) and handedness (χ2 = 0.82, p = 0.84).
ADHD severity between the ADHD and TD + ADHD groups differed
slightly but not signiﬁcantly with respect to total and inattentive scores
(t= 1.90, p= 0.06; t= 1.84, p= 0.07; t= 0.99, p= 0.33 for total, in-
attentive, and hyperactive CPRS scores, respectively) while tic severity
(t = 0.31, p = 0.76; t =−0.54, p= 0.59; K-W χ2 = ~0, p = 0.99 for
total, motor, and vocal YGTSS scores respectively) and OC-symptoms
(K-W χ2 = 1.52, p = 0.22) remained similar between the TD and
TD + ADHD groups.
Age of tic onset (t=−0.51, p= 0.62) and duration since tic onset
(t=−0.06, p= 0.95) did not differ signiﬁcantly between the TD and
the TD+ADHDgroup. For both analyses sexwas not balanced between
groups,mainly due to a lownumber of girlswith TDhavingbeen includ-
ed. This reﬂects the proportionately fewer girls affected by TD comparedto boys (Robertson, 2015). Sexwas included in themodel to account for
this imbalance, however, it was found not to affect the model signiﬁ-
cantly and was therefore subsequently removed.3.2. Spectral quality
Groups did not differ signiﬁcantly in mean voxel percentage GM,
WM or CSF in either ACC (F(3132) = 0.30, p = 0.83, F(3132) = 0.61,
p = 0.61 and F(3132) = 0.26, p = 0.85, respectively) or striatum
(F(3121) = 1.77, p = 0.16, F(3121) = 1.77, p = 0.16 and F(3121) = 1.73,
p=0.16, respectively). In the ACC voxel across all groups the tissue per-
centages were: GM 70 (7)%, WM 11 (2)% and CSF 18 (7)%. For the
striatal voxel these were GM 58 (7)%, WM 42 (7)% and CSF 1 (1)%.
To verify that the spectral quality did not differ between the groups,
we compared the CRLB estimated standard deviations in both of the
voxels, using a one-way ANOVA across the four groups. CRLB's did not
differ between groups in the ACC (F(3132) = 1.35, p= 0.26) or the stri-
atum (F(3121) = 0.37, p = 0.77). Furthermore all CRLB's were in the
range 3–7% SD, all SNR were N20 and all FWHM were in the range of
0.02–0.09 reﬂecting overall good quality of the ACC spectrum in all
four groups. For the striatum, CRLB's were in the range 5–17%, SNR
were N11 and FWHMwere in the range of 0.04–0.09.3.3. ACC
Age and sex had no signiﬁcant inﬂuence on the ANCOVAmodel and
were subsequently excluded. There was no group difference in
corrected glutamate levels ANOVA (F(3, 132) = 0.97, p = 0.41, Fig. 2).
There was no inﬂuence of IQ (p = 0.61), total CPRS ADHD severity T-
score (p = 0.56), inattentive CPRS T-score (p = 0.70), hyperactive
CPRS T-score (p= 0.48), CSBQ core autism symptom-score (p= 0.64)
or RBS compulsivity score (p= 0.92). Current medication use showed
no signiﬁcant effect on glutamate levels when any current medication
(p=0.65), current stimulantmedication (p=0.28) or current antipsy-
chotic medication (p= 0.56) were investigated.
Therewere no correlations in thosewith tics between corrected glu-
tamate concentrations and tic severity (total p= 0.77, motor p= 0.40,
vocal p=0.53), duration since (p=0.38) or age of onset (p=0.16). A
signiﬁcant positive correlation (rho = 0.35) between ACC glutamate
and CY-BOCS total score (p=0.02) was found (see Fig 3). This correla-
tion was also present for the obsessions (rho = 0.30, p = 0.045) and
compulsions (rho = 0.31, p= 0.04) severity scales separately. Howev-
er, the two subscales were highly correlated (rho = 0.55, p b 0.001).
However, none of the correlations with glutamate concentration sur-
vived correction for multiple comparisons (12 correlation analyses).
The analysis was limited to the participants that were administered
the CY-BOCS (n= 44, all with TD).3.4. Striatum
Similarly for the striatal analysis there were no signiﬁcant effects
of age or sex on glutamate levels. Group analysis revealed no differ-
ence in striatal corrected glutamate levels (F(3, 121) = 0.59, p= 0.62,
Fig. 2). Again there was no inﬂuence of IQ (p = 0.63), total CPRS
ADHD severity T-score (p = 0.78), inattentive CPRS T-score (p =
0.80), hyperactive CPRS T-score (p= 0.75), CSBQ core autism symp-
tom score (p = 0.37), RBS compulsivity score (p = 0.25) or current
medication use (any p = 0.73, stimulant p = 0.80 or antipsychotic
p = 0.06). There were no correlations between corrected glutamate
concentrations and tic severity (total p= 0.34, motor p= 0.46 vocal
p=0.22), duration since (p=0.19) or age of onset (p=0.08). There
was no association between glutamate and CY-BOCS total score
(rho =−0.25, p = 0.11).
Fig. 2. Boxplots of glutamate concentrations per group in the ACC and striatum. No group differences in glutamate levels were seen. ADHD, attention-deﬁcit/hyperactivity disorder; HC,
healthy controls; i.u., institutional units; TD, Tourette's disorder; TD + ADHD, Tourette's disorder and comorbid attention-deﬁcit/hyperactivity disorder.
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There were also no group differences in Glx concentration in either
the ACC or striatum (see Supplementary information for details).4. Discussion
This is theﬁrst study to investigate glutamate concentrations in both
TD and ADHD together. We found no group differences in ACC or left
striatal glutamate concentrations. The ﬁndings were not confounded
by any demographic differences between the groups, spectral quality,
medication use or OC-symptoms. Glutamate levels in the ACC correlatedFig. 3. Correlation of ACC glutamate concentration with obsessive–compulsive symptoms
(CY-BOCS total score) in participants with TD. ACC, anterior cingulate cortex; CY-BOCS,
Children's Yale-Brown Obsessive Compulsive Scale; i.u., institutional units; TD,
Tourette's disorder. The solid line and its shaded area denote the linear regression ﬁt
line and its 95% conﬁdence interval.with OC-symptoms within the participants with TD (n = 44) but did
not relate to either tic or ADHD measures of severity.
Only one previous study examined glutamate concentrations in TD
by investigating the combined Glx signal in children and adolescents
and they were unable to ﬁnd Glx differences in the brain regions inves-
tigated. In corroboration with results presented here (both Glx and glu-
tamate analyses) they found no difference in the putamen but
unfortunately did not also examine the ACC (DeVito et al., 2005). Previ-
ous studies did, however, suggest glutamate involvement in TD al-
though the nature of this is yet unclear with both hyper- and hypo-
glutamatergic states being hypothesized (Singer et al., 2010). For in-
stance, a post-mortem analysis by Anderson and colleagues (Anderson
et al., 1992) showed reduced glutamate levels in the GP and substantia
nigra of those with TD, while a study investigating serum glutamate
concentrations showed increased levels in adult TD patients compared
to controls (Janik et al., 2010). Our current ﬁndings do not support the
hypothesis of glutamatergic involvement in the fronto-striatal network
in TD.
The current study found no difference in those with ADHD com-
pared to healthy controls or any association between glutamate levels
andADHD severity scores in either the ACC or striatum. Previous studies
have been confounded bymethodological issues but do appear to show
increased Glx levels in both these regions in pediatric ADHD compared
to controls (Naaijen et al., 2015), an observation not replicated here, and
reduced striatal Glx in adults with ADHD (Maltezos et al., 2014). Associ-
ations with symptom severity have been reported previously in adults
with ADHD in which negative correlations between inattentive symp-
toms and glutamate-to-creatine ratios in the ACC (Dramsdahl et al.,
2011) or Glx levels in the basal ganglia (Maltezos et al., 2014) were re-
ported. However, these studies were performed in adults, who differ in
both ADHD symptoms (Polanczyk et al., 2007) and glutamate levels
(Horská et al., 2002) compared to children.
Possibly the most interesting ﬁnding of the current study, however,
is the potential positive correlation between ACC glutamate levels and
OC-symptomswithin participants with TD. The correlation was present
also for both the obsessions and compulsions subscales separately. This
suggests the association with ACC glutamate concentration relates to
the severity of OC-symptoms irrespective of these dimensions. Elevated
ACC glutamate may be associated with cognitive control deﬁcits related
to obsessions and compulsions (Botvinick et al., 2004). However, these
ﬁndings failed to survive correction for multiple comparisons so should
be interpreted with caution. Previous literature investigating associa-
tions with symptom severity in OCD samples have also shown positive
22 J. Naaijen et al. / NeuroImage: Clinical 13 (2017) 16–23correlations with glutamatergic compounds. For instance, correlations
betweenGlx levels in dorsal and rostral ACC (Yücel et al., 2008) and cau-
date nucleus (Gnanavel et al., 2014) and total symptomseverity asmea-
sured with the Y-BOCS were reported before, although only in adult
samples. Our ﬁndings should, however, only be interpreted in relation
to OC-symptoms within TD. No studies so far have examined gluta-
matergic compounds in childhood TD andOCD together. Further studies
are required to see if the current trend-ﬁndings extend toOC-symptoms
within pediatric OCD and across other disorders that exhibit similar be-
haviors, such as ASD. Furthermore, this is a child sample of participants
and how these ﬁndings relates to OC-symptoms in adult TDwill remain
unclear until further research is conducted.
The current study ranks among the ﬁrst to use MRS to investigate
brain neurochemical concentrations in TD and is the very ﬁrst to inves-
tigate glutamate concentrations in both TD andADHD together. Howev-
er, the study was limited by the small number of TD participants who
presented without ADHD/sub-threshold ADHD, these ﬁgures are in
line with what is expected given the high comorbidity rates of ADHD
in TD (Hirschtritt et al., 2015). It is unlikely that this signiﬁcantly hin-
dered the study as our null ﬁndings regarding tics and ADHD are sup-
ported by the lack of correlations between symptom severity and
glutamate levels. These results should not be extrapolated to adults as
glutamate concentrations change with age (Horská et al., 2002) and
adult ADHD and TD may well constitute speciﬁc presentations of TD
and ADHD that persist from childhood. Many participants were medi-
cated, which may alter glutamate levels. However, as the effect of cur-
rent medication use did not inﬂuence glutamate concentrations in
either the ACC or striatum medication use was unlikely to have con-
founded our results. There are several additional factors that may inﬂu-
ence glutamatergic signalling such as time of day, sleep, food intake etc.
for whichwe unfortunately could not control (Yuen et al., 2009; Zlotnik
et al., 2011). Futurework is needed to conﬁrm the inﬂuence of these fac-
tors. Most questionnaires were answered about an un-medicated peri-
od, however, a small number of parents opted to answer about a
medicated period as they were more familiar with this behavior, this
may have led to inconsistent measures of symptom severity in a few
cases. Finally, due to low spatial resolution in MRS studies (i.e. large
ROIs) it is difﬁcult to determine regionally speciﬁc glutamatergic alter-
ations. This is particularly relevant for the striatum ROI, whichmay con-
tain functionally independent areas with regard to caudate nucleus and
putamen. Further investigation should be undertaken to conﬁrm the re-
lation of OC-symptoms and glutamate concentrations in other disorders
(OCD, ASD) and also in adult cohorts to determine if the association
within TD is limited to children with TD or also present in adult TD.
In conclusion, we found no support for alterations in glutamatergic
transmission in the fronto-striatal circuit of children with either
ADHD, TD or a combined diagnosis. However, the current study sug-
gests glutamatergic alterations in the ACC in relation to OC-symptoms
within children with TD.
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